Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen Aranesp, Vectibix Setbacks Illustrate Risks Of Real World Trials

Executive Summary

Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products

You may also be interested in...

Strange Bedfellows: Amgen, J&J Work Together In Advance Of EPO Meeting

Amgen is working with Johnson & Johnson to ensure that a consistent message regarding the safety profile of erythropoiesis-stimulating agents is presented to FDA's Oncologic Drugs Advisory Committee

Aranesp Anemia Of Cancer Study Results Show Increased Mortality Risk

Amgen will continue to evaluate patients in its completed Phase III study of Aranesp in anemia of cancer after determining that use of darbepoetin alfa was associated with higher mortality risk

Panitumumab Pricing “Bookends” Will Be Avastin, Erbitux, Amgen Says

Amgen's pending oncologic panitumumab will be priced between Genentech's Avastin and Bristol-Myers Squibb/ImClone's Erbitux, Exec VP-Commercial Operations George Morrow said

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts